Investor Relations
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 28, 2021Times of India article highlights CoSara's tireless efforts to increase manufacturing of COVID-19 tests in response to deadly wave of infections
-
Apr 20, 2021Paper published in the Journal of Medical Microbiology utilizes Company's test in rapidly deployable mobile molecular diagnostics
-
Mar 25, 2021Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million
-
Mar 2, 2021Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR
-
Feb 25, 2021Clinical Reference Laboratory's FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2
-
Feb 23, 2021Company also elevates in-house Senior VP of Biochemistry to Chief Scientific Officer
-
Feb 16, 2021Company believes direct saliva to play a key role in high throughput, point of care, and at home applications
-
Jan 28, 2021The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process
-
Dec 22, 2020Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK
-
Dec 14, 2020Company anticipates Q4 revenue will significantly exceed previous quarter
-
Nov 17, 2020New tests expand global reach of Company COVID-19 test menu
-
Nov 16, 2020Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests